Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Status:
Not yet recruiting
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This research study involves a combination of three drugs given together as a possible
treatment for malignant rhabdoid tumor, atypical teratoid rhabdoid tumor, epithelioid
sarcoma, chordoma or other tumors that are deficient in one of two possible proteins, either
INI-1 (SMARCB1) or SMARCA4.
The names of the study drugs involved in this study are:
- Tazemetostat (TAZVERIK)
- Nivolumab (OPDIVO)
- Ipilimumab (YERVOY)